BioArctic
317.00 SEK
+1.54 %
Less than 1K followers
BIOA B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+1.54 %
-1.37 %
-13.01 %
+1.99 %
+13.13 %
+80.83 %
+3.26 %
+309.03 %
+993.10 %
BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.
Read moreMarket cap
28.12B SEK
Turnover
91.28M SEK
Revenue
2B
EBIT %
62.97 %
P/E
27.45
Dividend yield-%
0.63 %
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20/5
2026
Interim report Q1'26
28/5
2026
General meeting '26
29/5
2026
Annual dividend
All
Webcasts
Press releases
ShowingAll content types
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
Eisai prognosticerar 143,5 miljarder JPY i försäljning av Leqembi® för bolagets brutna räkenskapsår 2026 (april 2026 - mars 2027)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
